Laboratory of Diabetes and Vascular pathology, IIS-Fundación Jiménez Díaz, Medicine Department, Universidad Autónoma, 28040 Madrid, Spain.
Spanish Biomedical Research Centre on Diabetes and Associated Metabolic Disorders (CIBERDEM) Network, 28040 Madrid, Spain.
Nutrients. 2023 Feb 21;15(5):1067. doi: 10.3390/nu15051067.
Previous data suggested that anti-obesity interventions, such as percutaneous electric neurostimulation and probiotics, could reduce body weight and cardiovascular (CV) risk factors by attenuation of microbiota alterations. However, potential mechanisms of action have not been unveiled, and the production of short-chain fatty acids (SCFAs) might be involved in these responses. This pilot study included two groups of class-I obese patients (N = 10, each) who underwent anti-obesity therapy by percutaneous electric neurostimulations (PENS) and a hypocaloric diet (Diet), with/without the administration of the multi-strain probiotic ( LP115, LA14, and B3), for ten weeks. Fecal samples were used for SCFA quantification (by HPLC-MS) in relation to microbiota and anthropometric and clinical variables. In these patients, we previously described a further reduction in obesity and CV risk factors (hyperglycemia, dyslipemia) after PENS-Diet+Prob compared to PENS-Diet alone. Herein, we observed that the administration of probiotics decreased fecal acetate concentrations, and this effect may be linked to the enrichment of , spp., and . Additionally, fecal acetate, propionate, and butyrate are associated with each other, suggesting an additional benefit in colonic absorption. In conclusion, probiotics could help anti-obesity interventions by promoting weight loss and reducing CV risk factors. Likely, modification of microbiota and related SCFA, such as acetate, could improve environmental conditions and permeability in the gut.
先前的数据表明，抗肥胖干预措施，如经皮电神经刺激和益生菌，可通过减轻微生物群改变来降低体重和心血管（CV）危险因素。然而，潜在的作用机制尚未揭示，短链脂肪酸（SCFAs）的产生可能与这些反应有关。本研究包括两组 I 类肥胖患者（每组 10 例），他们接受经皮电神经刺激（PENS）和低热量饮食（Diet）的抗肥胖治疗，同时/不服用多菌株益生菌（LP115、LA14 和 B3），持续十周。粪便样本用于通过 HPLC-MS 定量 SCFA，以评估微生物群和人体测量学及临床变量。在这些患者中，我们之前描述了与单独使用 PENS-Diet 相比，PENS-Diet+Prob 后肥胖和 CV 危险因素（高血糖、血脂异常）进一步降低。在此，我们观察到益生菌的使用降低了粪便乙酸浓度，这种作用可能与 spp.和 spp.的富集有关。此外，粪便乙酸、丙酸和丁酸彼此相关，提示结肠吸收有额外的益处。总之，益生菌可能通过促进体重减轻和降低 CV 危险因素来帮助抗肥胖干预。可能是微生物群的改变和相关的 SCFA（如乙酸）的改变改善了肠道的环境条件和通透性。
